0000000001047012

AUTHOR

M. Stelljes

showing 2 related works from this author

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk C…

2017

Patients with chronic lymphocytic leukemia with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective European Society for Blood and Marrow Transplantation registry study shows that young high cytogenetic risk responsive patients with human leukocyte antigen-matched donors have a high 8-year progression-free survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients.Background: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free sur…

MaleOncologyCancer ResearchTransplantation ConditioningBLOODCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatmentChronic lymphocytic leukemiaMedizinMULTICENTERKaplan-Meier EstimateHematopoietic stem cell transplantationTHERAPYchemistry.chemical_compound0302 clinical medicineHLA AntigensRisk FactorsIBRUTINIBeducation.field_of_studyHazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedPrognosisRELAPSED CLLTissue DonorsEUROPEAN-SOCIETY3. Good healthRisk factor analysisTreatment OutcomeOncology030220 oncology & carcinogenesisIbrutinibSURVIVALFemaleRefractory Chronic Lymphocytic LeukemiaAdultmedicine.medical_specialty3122 CancersPopulationHLA-matched donorMARROW TRANSPLANTATION03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterNon-relapse mortalityInternal medicinemedicineHumansTransplantation HomologouseducationAgedRetrospective StudiesChromosome Aberrationsbusiness.industryKinase- and BCL2 inhibitor refractorymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryTransplantationchemistryMATCHED UNRELATED DONORdel(17p)FOLLOW-UPbusiness030215 immunology
researchProduct

Supplementary Material for: Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelate…

2019

There is no established standard for selection of mismatched unrelated donors. Indirect recognition of HLA mismatches can be predicted using the model of “Predicted Indirectly ReCognizable HLA Epitopes” (PIRCHE). We performed a multicenter retrospective study evaluating the impact PIRCHE on outcome after allogeneic stem cell transplantation (allo-HSCT) from single mismatched (HLA 9/10 matched) unrelated donors. The study cohort included 424 adult recipients of HLA 9/10 matched unrelated donor transplants (9/10 MUD), treated for AML or MDS at 6 transplant centers across Germany. Detection of PIRCHE was associated with lower overall survival (OS) (47 vs. 57%, p = 0.04), higher non-relapse mor…

researchProduct